GlaxoSmithKline Pharmaceuticals Limited is a subsidiary of the UK-based GSK plc, operating as a leading global biopharma company that brings together science and talent to fight disease. The company has a long-term strategic goal to positively impact the health of 2.5 billion people across the globe by the end of 2030. Its culture is built on being ambitious for patients, staying accountable for its impact, and consistently doing the right thing for people, patients, and all stakeholders. GSK India operates with a diversified portfolio that includes a wide range of locally manufactured general medicines, alongside imported vaccines and specialty medicines. It is a market leader in private vaccines and dermatology and holds a strong leadership position in the anti-infectives segment in India's pharmaceutical industry. Through its state-of-the-art manufacturing facility in Nashik and an extensive distribution network, the company's products reach over 1,400 towns across the country.;

MD/CEO

Bhushan Akshikar

Founded in

1924

NSE symbol

GLAXO

Industry

Shareholding Pattern

Dec '24

Mar '25

Jun '25

Sep '25

Dec '25

Promoters
75.00%
Retail And Others
12.66%
Mutual Funds
4.77%
Foreign Institutions
4.64%
Other Domestic Institutions
2.93%

Mutual Funds Invested (4)

Fund name	AUM%
Nippon India Pharma Fund Direct Growth	2.83
Tata India Pharma & Healthcare Fund Direct Growth	1.82
Baroda BNP Paribas Midcap Fund Direct Growth	1.63
JM Midcap Fund Direct Growth	1.34

Similar stocks

Stock	Mkt price (1D)	52 week performance	Market cap	P/E ratio	P/B ratio
Sun Pharmaceutical IndustriesSUNPHARMA	₹1,685.20 -43.30 (2.51%)	L H	4,14,713.05	37.86	5.33
Torrent PharmaceuticalsTORNTPHARM	₹3,976.20 -135.10 (3.29%)	L H	1,39,052.00	61.2	16.46
LupinLUPIN	₹2,262.60 -12.30 (0.54%)	L H	1,03,944.24	22.26	5.29
Dr Reddy's LaboratoriesDRREDDY	₹1,213.10 +3.50 (0.29%)	L H	1,00,926.72	18.27	2.8

ScoutQuest • 2 days ago

GlaxoSmithKline Pharma faces Rs 2.01 Cr TDS demand for AY 2020-21. Demand includes Rs 1.11 Cr TDS, Rs 0.90 Cr interest; company to appeal.

ScoutQuest • 1 week ago

GlaxoSmithKline Pharma Ltd faces Rs 23.2 cr tax demand for AY 2023-24 post scrutiny. Company plans to appeal; no immediate financial impact reported.

ScoutQuest • 2 weeks ago

GlaxoSmithKline Pharma CFO resigned effective March 11, 2026 for new role as Asia Pacific Finance Head. Board requested to record resignation, complete regulatory filings, and expressed appreciation to MD.

MarketScreener • 1 month ago

GlaxoSmithKline Pharmaceuticals appoints Ronojit Biswas as whole-time director & CFO. Juby Chandy steps down as whole-time director & CFO of the company.

ScoutQuest • 1 month ago

DRI searched GSK Pharma's Mumbai office on Feb 27-28 under Customs Act 1962. GSK Pharma's operations remain unaffected; full cooperation extended to authorities.

ScoutQuest • 1 month ago

GlaxoSmithKline Pharmaceuticals faces Rs. 379.3 crore GST demand, including Rs. 189.6 crore penalty. The company is assessing next steps; no immediate financial impact reported.

BSE • 1 month ago

GlaxoSmithKline Pharmaceuticals Ltd reported Q3 FY2026 revenue crossing INR 1,000 crores, driven by 10% growth led by key brands and vaccines. The company highlighted progress in oncology and specialty portfolios with new launches like Zejula and Jemperli, aiming for sustained double-digit growth.

Moneycontrol • 2 months ago

GlaxoSmithKline Pharma's Dec 2025 net sales rose 8.1% Y-o-Y to Rs 1,022.6 cr; net profit surged 21.3% to Rs 277.2 cr. EPS increased to Rs 16.36 from Rs 13.49; shares gave 17.5% return in 12 months, closing at Rs 2,516.2 on Feb 6, 2026.

BSE • 2 months ago

GSK Pharma posted 8.1% revenue growth in Q3 FY26, driven by General Medicine, Vaccines, and Specialty segments with improved EBITDA margin of 35.9%. Key brands like Augmentin, Calpol, and Ceftum gained market share, while Oncology and Pediatric Vaccines led growth. PAT grew 21.3% with Rs.16.36 EPS.

Livesquawk • 2 months ago

GlaxoSmithKline Pharma reports Q3 revenue of ₹10.4B, up from ₹9.5B YOY. This growth highlights strong performance in the pharmaceutical sector.

2026

Feb

Quarterly Result

Release date

Check latest financial

2025

Nov

Quarterly Result

Release date

Check latest financial

Aug

Quarterly Result

Release date

Check latest financial

30
May
Dividend
Ex date
₹42.00
per share

For each share you hold, you will receive ₹42.00

Dividend amount₹42.00 per share

Dividend TypeFinal

Ex Date30 May ‘25

Record Date30 May ‘25

Announcement date13 May ‘25

13
May
Dividend
Announced
₹42.00
per share

For each share you hold, you will receive ₹42.00

Dividend amount₹42.00 per share

Dividend TypeFinal

Ex Date30 May ‘25

Record Date30 May ‘25

Announcement date13 May ‘25

2024

7
Nov
Dividend
Ex date
₹12.00
per share

For each share you hold, you will receive ₹12.00

Dividend amount₹12.00 per share

Dividend TypeSpecial

Ex Date7 Nov ‘24

Record Date7 Nov ‘24

Announcement date29 Oct ‘24

29
Oct
Dividend
Announced
₹12.00
per share

For each share you hold, you will receive ₹12.00

Dividend amount₹12.00 per share

Dividend TypeSpecial

Ex Date7 Nov ‘24

Record Date7 Nov ‘24

Announcement date29 Oct ‘24

31
May
Dividend
Ex date
₹32.00
per share

For each share you hold, you will receive ₹32.00

Dividend amount₹32.00 per share

Dividend TypeFinal

Ex Date31 May ‘24

Record Date31 May ‘24

Announcement date17 May ‘24

17
May
Dividend
Announced
₹32.00
per share

For each share you hold, you will receive ₹32.00

Dividend amount₹32.00 per share

Dividend TypeFinal

Ex Date31 May ‘24

Record Date31 May ‘24

Announcement date17 May ‘24

Events calendar

View upcoming events in other stocks

Home>Stocks>GlaxoSmithKline Pharmaceuticals

Vaishnavi Tech Park, South Tower, 3rd FloorSarjapur Main Road, Bellandur, Bengaluru – 560103Karnataka

Download the App

Share Market

Indices

F&O

Mutual Funds

ETFs

Funds By Groww

Calculators

IPO

Miscellaneous

NIFTY Bank Options SBI Options Bajaj Finance Options Axis Bank Options Hindustan Unilever Options NIFTY Bank Futures Finnifty Futures ITC Futures ICICI Bank Futures Biocon Futures Indusind Bank Futures Crude Oil Mini Future Price Gold Petal Future Price Silver Micro Future Price Nickel Future Price Natural Gas Mini MCX Option Chain Copper MCX Option Chain

NIFTY 50 Options HDFC Bank Options Wipro Options DLF Options REC Options Yes Bank Futures Zomato Futures Ashok Leyland Futures HDFC Bank Futures UPL Futures Adani Enterprises Futures Gold Future Price Natural Gas Future Price Zinc Future Price Gold MCX Option Chain Gold Mini MCX Option Chain

Bse Sensex Options Tata Steel Options NTPC Options Bajaj Auto Options Indusind Bank Options Tata Motors Futures Infosys Futures Asian Paints Futures Lupin Futures Cipla Futures IDFC First Bank Futures Gold Mini Future Price Natural Gas Mini Future Price Copper Future Price Crude Oil MCX Option Chain Silver MCX Option Chain

Finnifty Options Infosys Options Asian Paints Options Coal India Options Ashok Leyland Options Tata Steel Futures BSE Sensex Futures Wipro Futures DLF Futures Bajaj Finance Futures Piramal Enterprises Futures Gold Ten Future Price Silver Future Price Aluminium Future Price Crude Oil Mini MCX Option Chain Silver Mini MCX Option Chain

Tata Motors Options ITC Options ICICI Bank Options Adani Enterprises Options NIFTY 50 Futures Coal India Futures Axis Bank Futures Vedanta Futures Reliance Industries Futures Hindustan Copper Futures Crude Oil Future Price Gold Guinea Future Price Silver Mini Future Price Electricity Future Price Natural Gas MCX Option Chain Zinc MCX Option Chain

MF Screener Debt Mutual Funds Best Multicap Mutual funds Best Contra Mutual funds Best Conservative Mutual funds SBI Contra Fund Nippon India Nifty 500 Momentum 50 Index Fund HDFC Balanced Advantage Fund Quant Mid Cap Fund Bank of India Small Cap Fund Quant Multi Asset Fund Nippon India TATA Bandhan Edelweiss HSBC Union Quantum Shriram

Compare Mutual Funds Best Debt Mutual funds Best Large Cap Mutual funds Best Value Mutual funds Parag Parikh Flexi Cap Fund HDFC Mid Cap Opportunities Fund Motilal Oswal Nifty India Defence Index Fund ICICI Prudential India Opportunities Fund Kotak Small Cap Fund Canara Robeco Bluechip Equity Fund GrowwMF Motilal Oswal Aditya Birla Axis Bank of India Bajaj Finserv Helios ITI Trust

MF Knowledge Centre Best Equity Mutual funds Best Small Cap Mutual funds Best Arbitrage Mutual funds Motilal Oswal Midcap Fund SBI Small Cap Fund HDFC Small Cap Fund Kotak Multicap Fund ICICI Prudential Infrastructure Fund Bandhan Nifty Alpha 50 Index Fund SBI Quant Mirae Asset DSP Baroda BNP Paribas Mahindra Manulife Sundaram Samco Taurus

Mutual Fund Houses Best Hybrid Mutual funds Best ELSS Mutual funds Best Dividend Yield Mutual funds Nippon India Small Cap Fund HDFC Flexi Cap Fund Tata Small Cap Fund Tata Ethical Fund Mirae Asset ELSS Tax Saver Fund Quant Infrastructure Fund HDFC PPFAS UTI Kotak Mahindra Zerodha Invesco Navi PGIM

Mutual Funds Categories Best MidCap Mutual funds Best Sector Mutual funds Best Aggressive Mutual funds Quant Small Cap Fund SBI Magnum Children's Benefit Fund UTI Nifty 50 Index Fund JM Flexicap Fund HSBC Small Cap Fund Franklin India Multi Cap Fund ICICI Prudential LIC Canara Robeco Whiteoak Franklin Templeton NJ JM 360 One

International Silver Midcap Liquid

Debt Index Bank Nifty Nifty IT

Equity Nifty 50 Nifty Metal Nifty Auto

Commodity Nifty Next 50 Healthcare Groww

Gold Sensex Defence

What is IPO?IPO Subscription Status IPO Allotment Status

Open IPOs How to Apply for an IPO

Upcoming IPOs What is Grey Market Premium?

Closed IPOs Mainboard IPOs

IPO GMP SME IPOs

Others:

NSEBSEMCXTerms and ConditionsPolicies and ProceduresRegulatory & Other InfoPrivacy PolicyDisclosureSMART ODRDownload FormsInformation Security PracticesInvestor Charter and GrievanceBug Bounty

Mutual Funds:

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z Others

Stocks:

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z Others

About Groww

Groww is India's largest Stock Broker with more than 1.4 crore active customers where users can find their investment solutions pertaining to mutual funds, stocks, US Stocks, ETFs, IPO, and F&Os, to invest their money without hassles.

Groww objectively evaluates stocks and mutual funds and does not advise or recommend any stocks, mutual funds or portfolios. Investors shall invest at their own discretion, will and consent. Groww, at any time, does not guarantee fixed returns on the capital invested.

Groww helps investors -

· By providing 100% paperless online free Demat and trading account opening

· By providing an objective evaluation of products available on the platform

· By being transparent about fees and charges involved while investing in a product

· By offering decision-making assistance by providing technical analysis with advanced charts, well-designed line & candlestick charts that indicate share price movements, and market indices, along with more details about all registered and listed companies

SECURE TRANSACTIONS ON GROWW

All transactions on Groww are safe and secure. Users can invest through SIP or Lumpsum using Netbanking through all supported banks. It uses BSE Star MF (with Member code 11724) as transaction platform.

TRADE AND INVEST SECURELY WITH GROWW

Stocks, Mutual fund investments, F&Os, etc., are very popular with individual investors because of their numerous benefits. On Groww, an investor can -

- Invest in Nifty 50 (NSE) & Sensex (BSE) listed stocks

- Diversify across multiple stocks and other instruments

- Start SIP with any amount (as low as Rs. 500)

- Switch regular funds to direct funds

- Start automated monthly investments (SIP), and benefit from many more features

All type of mutual funds are available on Groww.

INVESTING IN MUTUAL FUND PORTFOLIOS

Portfolio is collection of mutual funds designed to meet your investment goals. Investing in mutual fund portfolios helps you in diversifying your investments and reduces the risk. Portfolios also help you in assigning an investment goals and make it easy for you to save for and achieve your goals. You can create a portfolio yourself or ask an expert to build it for you.

ATTENTION INVESTORS

1. For Stock Broking Transaction 'Prevent unauthorised transactions in your account --> Update your mobile numbers/email IDs with your stock brokers. Receive information of your transactions directly from Exchange on your mobile/email at the end of the day...Issued in the interest of Investors.

2. For Depository Transaction 'Prevent Unauthorized Transactions in your demat account --> Update your Mobile Number with your Depository Participant. Receive alerts on your Registered Mobile for all debit and other important transactions in your demat account directly from CDSL/NSDL on the same day...Issued in the interest of investors.

3. KYC is a one time exercise while dealing in securities markets - once KYC is done through a SEBI registered intermediary (Broker, DP, Mutual Fund etc.), you need not undergo the same process again when you approach another intermediary.

4. If you are subscribing to an IPO, there is no need to issue a cheque. Please write the Bank account number and sign the IPO application form to authorize your bank to make payment in case of allotment. In case of non allotment the funds will remain in your bank account.

· Investors should be cautious on unsolicited emails and SMS advising to buy, sell or hold securities and trade only on the basis of informed decision. Investors are advised to invest after conducting appropriate analysis of respective companies and not to blindly follow unfounded rumours, tips etc. Further, you are also requested to share your knowledge or evidence of systemic wrongdoing, potential frauds or unethical behaviour through the anonymous portal facility provided on BSE & NSE website.

· Awareness regarding guidelines on Margin collection

1. Stock Brokers can accept securities as margin from clients only by way of pledge in the depository system w.e.f. September 1, 2020.

2. Update your mobile number & email Id with your stock broker/depository participant and receive OTP directly from depository on your email id and/or mobile number to create pledge.

3. Pay 20% upfront margin of the transaction value to trade in cash market segment.

4. Investors may please refer to the Exchange's Frequently Asked Questions (FAQs) issued vide circular reference NSE/INSP/45191 dated July 31, 2020 and NSE/INSP/45534 dated August 31, 2020 and other guidelines issued from time to time in this regard.

5. Check your Securities /MF/ Bonds in the consolidated account statement issued by NSDL/CDSL every month.

Issued in the interest of Investors

DISCLAIMER

Groww Invest Tech Pvt. Ltd. (Formerly known as Nextbillion Technology Pvt. Ltd) (CIN: U65100KA2016PTC092879) is a member of NSE & BSE & MCX with SEBI Registration no: INZ000301838, Depository Participant of CDSL Depository with SEBI Registration no: IN-DP-417-2019 and Mutual Fund distributor with AMFI Registration No: ARN-111686. Registered office and Correspondence office - Vaishnavi Tech Park, South Tower, 3rd floor, Sarjapur Main Road, Bellandur, Bengaluru – 560103, Karnataka. For any grievances related to Stock Broking/DP, please write to [email protected] , please ensure you carefully read the Risk Disclosure Document as prescribed by SEBI.

Procedure to file a complaint on SEBI SCORES: Register on the SCORES portal. Mandatory details for filing complaints on SCORES: Name, PAN, Address, Mobile Number, E-mail ID. Benefits: Effective Communication, Speedy redressal of the grievances.

Groww Invest Tech Pvt. Ltd. (Formerly known as Nextbillion Technology Pvt. Ltd) makes no warranties or representations, express or implied, on products offered through the platform. It accepts no liability for any damages or losses, however caused, in connection with the use of, or on the reliance of its product or related services. Unless otherwise specified, all returns, expense ratio, NAV, etc are historical and for illustrative purposes only. Future will vary greatly and depends on personal and market circumstances. The information provided by our blog is educational only and is not investment or tax advice.

Investment in Securities Market are subject to market risks, read all the related documents carefully before investing

Mutual fund investments are subject to market risks. Please read all scheme related documents carefully before investing. Past performance of the schemes is neither an indicator nor a guarantee of future performance.

India's largest Stock Broker by active users on NSE as of June 30, 2025. Refer: NSE's Arbitration status

Terms and conditions of the website/app are applicable. Privacy policy of the website is applicable.

GlaxoSmithKline Pharmaceuticals

Performance

Fundamentals

Financials

About

Shareholding Pattern

Mutual Funds Invested (4)

Similar stocks

30MayDividendEx date₹42.00per share

13MayDividendAnnounced₹42.00per share

7NovDividendEx date₹12.00per share

29OctDividendAnnounced₹12.00per share

31MayDividendEx date₹32.00per share

17MayDividendAnnounced₹32.00per share

About Groww

30
May
Dividend
Ex date
₹42.00
per share

13
May
Dividend
Announced
₹42.00
per share

7
Nov
Dividend
Ex date
₹12.00
per share

29
Oct
Dividend
Announced
₹12.00
per share

31
May
Dividend
Ex date
₹32.00
per share

17
May
Dividend
Announced
₹32.00
per share